Ventus raises RA-led $100M series B that will enable human trials, open path to IPO

Less than a year after emerging from stealth with $60 million, Ventus has added $100 million to its coffers in a series B round that could drive two programs into the clinic and enable the company to advance additional candidates from its two structural biology drug discovery platforms. 

President and CEO Marcelo Bigal told BioCentury the round could provide runway through 2024, though the company may pursue an IPO as early as next year. ...